Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.

Date publication

mai 2023

Journal

Neurology(R) neuroimmunology & neuroinflammation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36810163

Résumé

Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology.

Mots clés

Humans, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Multiple Sclerosis, drug therapy, Leukocytes, Mononuclear, Antibodies, Monoclonal, Humanized, therapeutic use

Référence

Neurol Neuroimmunol Neuroinflamm. 2023 05;10(3):